RespireRx Pharmaceuticals (OTCQB:RSPI) CFO Jeff Margolis tells Proactive the Glen Rock, New Jersey-based group is advancing its slew of therapeutics throughout the clinical pipeline including a synthetic form of cannabinoid called dronabinol.
Margolis says it aims to move to a Phase 3 clinical study to treat obstructive sleep apnea (OSA) with dronabinol. Meanwhile, Margolis says it will look to conduct a Regulation A offering to raise up to $7.5 million to fund its pipeline.